• 1
    Zou, W., Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 2005. 5: 263274.
  • 2
    Croci, D. O., Zacarías Fluck, M. F., Rico, M. J., Matar, P., Rabinovich, G. A. and Scharovsky, O. G., Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol. Immunother. 2007. 56: 16871700.
  • 3
    Kryczek, I., Wei, S., Zou, L., Altuwaijri, S., Szeliga, W., Kolls, J., Chang, A. and Zou, W., Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol. 2007. 178: 67306733.
  • 4
    Kato, T., Furumoto, H., Ogura, T., Onishi, Y., Irahara, M., Yamano, S., Kamada, M. and Aono, T., Expression of IL-17 mRNA in ovarian cancer. Biochem. Biophys. Res. Commun. 2001. 282: 735738.
  • 5
    Numasaki, M., Watanabe, M., Suzuki, T., Takahashi, H., Nakamura, A., McAllister, F., Hishinuma, T. et al., IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J. Immunol. 2005. 175: 61776189.
  • 6
    Ferrara, N. and Kerbel, R. S., Angiogenesis as a therapeutic target. Nature 2005. 438: 967974.
  • 7
    Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M. and Stockinger, B., TGFb in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006. 24: 179189.
  • 8
    Veldhoen, M., Hocking, R. J., Flavell, R. A. and Stockinger, B., Signals mediated by transforming growth factor-b initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat. Immunol. 2006. 7: 11511156.
  • 9
    Dong, C., Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat. Rev. Immunol. 2006. 6: 329333.
  • 10
    Tajima, M., Wakita, D., Noguchi, D., Chamoto, K., Yue, Z., Fugo, K., Ishigame, H. et al., IL-6-dependent spontaneous proliferation is required for the induction of colitogenic IL-17-producing CD8+T cells. J. Exp. Med. 2008. 205: 10191027.
  • 11
    Michel, M. L., Keller, A. C., Paget, C., Fujio, M., Trottein, F., Savage, P. B., Wong, C. H. et al., Identification of an IL-17-producing NK1.1neg iNKT cell population involved in airway neutrophilia. J. Exp. Med. 2007. 204: 9951001.
  • 12
    Romani, L., Fallarino, F., De Luca, A., Montagnoli, C., D'Angelo, C., Zelante, T., Vacca, C. et al., Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 2008. 451: 211215.
  • 13
    Ye, P., Rodriguez, F. H., Kanaly, S., Stocking, K. L., Schurr, J., Schwarzenberger, P., Oliver, P. et al., Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J. Exp. Med. 2001. 194: 519527.
  • 14
    Ouyang, W., Kolls, J. K., Zheng, Y., The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008. 28: 454467.
  • 15
    Nakae, S., Komiyama, Y., Nambu, A., Sudo, K., Iwase, M., Homma, I., Sekikawa, K. et al., Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002. 17: 375387.
  • 16
    Nishimura, T., Iwakabe, K., Sekimoto, M., Ohmi, Y., Yahata, T., Nakui, M., Sato, T. et al., Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 1999. 190: 617627.
  • 17
    Ikeda, H., Chamoto, K., Tsuji, T., Suzuki, Y., Wakita, D., Takeshima, T. and Nishimura, T., The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci. 2004. 95: 697703.
  • 18
    Wakita, D., Chamoto, K., Ohkuri, T., Narita, Y., Ashino, S., Sumida, K., Nishikawa, H. et al., IFN-gamma-dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model. Carcinogenesis 2009. 30: 14081415.
  • 19
    Chamoto, K., Wakita, D., Narita, Y., Zhang, Y., Noguchi, D., Ohnishi, H., Iguchi, T. et al., An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy. Cancer Res. 2006. 66: 18091817.
  • 20
    Zhang, Y., Wakita, D., Chamoto, K., Narita, Y., Matsubara, N., Kitamura, H. and Nishimura, T., Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs. Int. Immunol. 2007. 19: 151161.
  • 21
    Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B. et al., IL-23 promotes tumour incidence and growth. Nature 2006. 442: 461465.
  • 22
    Kortylewski, M., Xin, H., Kujawski, M., Lee, H., Liu, Y., Harris, T., Drake, C. et al., Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009. 15: 114123.
  • 23
    Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J. and Schreiber, R. D., IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001. 410:11071111.
  • 24
    Dunn, G. P., Koebel, C. M. and Schreiber, R. D., Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 2006. 6: 836848.
  • 25
    Gao, Y., Yang, W., Pan, M., Scully, E., Girardi, M., Augenlicht, L. H., Craft, J. and Yin, Z., Gamma delta T cells provide an early source of interferon g in tumor immunity. J. Exp. Med. 2003. 198: 433442.
  • 26
    Girardi, M., Oppenheim, D. E., Steele, C. R., Lewis, J. M., Glusac, E., Filler, R., Hobby, P. et al., Regulation of cutanous malignancy by gd T cells. Science 2001. 294: 605609.
  • 27
    Strid, J., Roberts, S. J., Filler, R. B., Lewis, J. M., Kwong, B. Y., Schpero, W., Kaplan, D. H. et al., Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis. Nat. Immunol. 2008. 9: 146154.
  • 28
    de Visser, K. E., Eichten, A. and Coussens, L. M., Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 2006. 6: 2437.
  • 29
    Mantovani, A., Allavena, P., Sica, A. and Balkwill, F., Cancer-related inflammation. Nature 2008. 454: 436444.
  • 30
    Daniel, D., Meyer-Morse, N., Bergsland, E. K., Dehne, K., Coussens, L. M. and Hanahan, D., Immune enhancement of skin carcinogenesis by CD4+T cells. J. Exp. Med. 2003. 197: 10171028.
  • 31
    Girardi, M., Glusac, E., Filler, R. B., Roberts, S. J., Propperova, I., Lewis, J., Tigelaar, R. E. and Hayday, A. C., The distinct contributions of murine T cell receptor (TCR)gammadelta+and TCRalphabeta+T cells to different stages of chemically induced skin cancer. J. Exp. Med. 2003. 198: 747755.
  • 32
    Roberts, S. J., Ng, B. Y., Filler, R. B., Lewis, J., Glusac, E. J., Hayday, A. C., Tigelaar, R. E. and Girardi, M., Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis. Proc. Natl. Acad. Sci. USA 2007. 104: 67706775.
  • 33
    DeNardo, D. G., Barreto, J. B., Andreu, P., Vasquez, L., Tawfik, D., Kolhatkar, N. and Coussens, L. M., CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009, 16: 91102.
  • 34
    Nam, J. S., Terabe, M., Kang, M. J., Chae, H., Voong, N., Yang, Y. A., Laurence, A. et al., Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res. 2008. 68: 39153923.
  • 35
    Yusuf, N., Nasti, T. H., Katiyar, S. K., Jacobs, M. K., Seibert, M. D., Ginsburg, A. C., Timares, L. et al., Antagonistic roles of CD4+and CD8+T-cells in 7,12-dimethylbenz(a)anthracene cutaneous carcinogenesis. Cancer Res. 2008. 68: 39243930.
  • 36
    Martin, B., Hirota, K., Cua, D. J., Stockinger, B. and Veldhoen, M., Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity 2009. 31: 321330.
  • 37
    Ribot, J. C., deBarros, A., Pang, D. J., Neves, J. F., Peperzak, V., Roberts, S. J., Girardi, M. et al., CD27 is a thymic determinant of the balance between interferon-gamma- and interleukin 17-producing gammadelta T cell subsets. Nat. Immunol. 2009. 10: 427436.
  • 38
    Haas, J. D., González, F. H., Schmitz, S., Chennupati, V., Föhse, L., Kremmer, E., Förster, R. and Prinz, I., CCR6 and NK1.1 distinguish between IL-17A and IFN-gamma-producing gammadelta effector T cells. Eur. J. Immunol. 2009. 39: 34883497.
  • 39
    Peng, G., Wang, H. Y., Peng, W., Kiniwa, Y., Seo, K. H. and Wang, R. F., Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 2007. 27: 334348.
  • 40
    Kryczek, I., Banerjee, M., Cheng, P., Vatan, L., Szeliga, W., Wei, S., Huang, E. et al., Phenotype, distribution, generation, functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009. 6: 11411149.
  • 41
    Miyahara, Y., Odunsi, K., Chen, W. Peng, G., Matsuzaki, J. and Wang, R. F., Generation and regulation of human CD4+IL-17-producing T cells in ovarian Cancer. Proc. Natl. Acad. Sci. USA 2008. 105: 1550515510.
  • 42
    Wu, S., Rhee, K. J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H. R., Huso, D. L. et al., A human colonic commensal promotes colon tumorignesis via activation of T helper type 17 T cell responses. Nat. Med. 2009. 15: 10161022.
  • 43
    Wang, L., Yi, T., Kortylewski, M., Pardoll, D. M., Zeng, D., Yu, H., IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 2009. 206: 14571464.
  • 44
    Martin-Orozco, N., Muranski, P., Chung, Y., Yang, X. O., Yamazaki, T., Lu, S., Hwu, P. et al., T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009. 31: 787798.
  • 45
    Hinrichs, C. S., Kaiser, A., Paulos, C. M., Cassard, L., Sanchez-Perez, L., Heemskerk, B., Wrzesinski, C. et al., Type 17 CD8+T cells display enhanced anti-tumor immunity. Blood 2009. 114: 596599.
  • 46
    Muranski, P., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M. et al., Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008. 112: 362373.